In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

Hello, and welcome to the Life Science Investor Forum . On behalf of OTC Markets and our co-host, Zacks Small Cap Research , we are very pleased you have joined us. The next presentation of the day is ...

Courts may deny motions for judgment notwithstanding the verdict when a jury reaches a reasonable decision based on evidence of a patient's failure to follow a prescribed treatment plan.

The PAUSE-URO study evaluated the safety of a new protocol for patients using direct oral anticoagulants (DOACs) prior to elective urologic surgery.

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...

Acute pulmonary embolism (PE) can be a sudden, life-threatening emergency, and recognising it early can mean the difference between recovery and death. A new joint clinical practice guideline from the ...

Understanding your clonazepam dosage is an important step in managing your health. This guide breaks down the standard strengths and instructions found in the drug’s prescribing information, helping ...